6ER-008 Development of a risk-sharing model based on the clinical performance of onasemnogene abeparvovec (Zolgensma) | European Journal of Hospital Pharmacy

Subscribe
Log In More

Log in via Institution
Log in via OpenAthens
Log in via EAHP

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Close More
Main menu

Latest content

Current issue

Archive

Authors

About
Subscribe
Log in More

Log in via Institution
Log in via OpenAthens
Log in via EAHP

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
BMJ Journals

Article metrics

Section 6: Education and research

6ER-008 Development of a risk-sharing model based on the clinical performance of onasemnogene abeparvovec (Zolgensma)

Free

Online download statistics by month:

Online download statistics by month: March 2022 to September 2024

	Abstract	Full	Pdf
Mar 2022	34	0	5
Apr 2022	95	0	14
May 2022	43	0	20
Jun 2022	30	0	8
Jul 2022	38	0	9
Aug 2022	21	0	3
Sep 2022	38	0	7
Oct 2022	32	0	2
Nov 2022	39	0	8
Dec 2022	33	0	8
Jan 2023	44	0	5
Feb 2023	17	0	7
Mar 2023	46	0	6
Apr 2023	23	0	6
May 2023	18	0	4
Jun 2023	8	0	1
Jul 2023	32	0	7
Aug 2023	34	0	3
Sep 2023	25	0	4
Oct 2023	34	0	3
Nov 2023	18	0	2
Dec 2023	20	0	2
Jan 2024	22	0	5
Feb 2024	6	0	3
Mar 2024	24	0	2
Apr 2024	32	0	5
May 2024	19	0	4
Jun 2024	14	0	1
Jul 2024	8	0	3
Aug 2024	7	0	2
Sep 2024	13	0	1
Total	867	0	160